Association of Hemostatic Markers with Atrial Fibrillation: A Meta-Analysis and Meta-Regression

Na Wu¹,²*, Shifei Tong³*, Ying Xiang¹,², Long Wu¹,², Bin Xu¹,², Yao Zhang¹,², Xiangyu Ma¹,², Yafei Li¹,², Zhiyuan Song³‡, Li Zhong³‡*

¹ Department of Epidemiology, College of Preventive Medicine, Third Military Medical University, Chongqing, People’s Republic of China, ² Evidence-based Medicine and Clinical Epidemiology Center, Third Military Medical University, Chongqing, People’s Republic of China, ³ Department of Cardiology, Southwest Hospital, Third Military Medical University, Chongqing, People’s Republic of China

☯ These authors contributed equally to this work.
‡ These authors jointly directed the project.
* zysong2010@126.com (ZS); zhongli28@hotmail.com (LZ)

Abstract

Background

There is growing evidence that indicates the presence of a prothrombotic state in atrial fibrillation (AF). However, the role of hemostatic markers in AF remains inconclusive.

Methods

We conducted a meta-analysis of observational studies to evaluate the association between hemostatic markers and AF. A meta-regression was performed to explore potential sources of heterogeneity.

Results

A total of 59 studies met our inclusion criteria for the meta-analysis. For platelet activation, increased circulating platelet factor-4, β-thromboglobulin (BTG) and P-selectin were significantly higher in AF cases compared with controls (standardized mean difference [SMD] [95% confidence interval (CI)]: 1.72[0.96–2.49], 1.61[1.03–2.19] and 0.50[0.23–0.77], respectively). For coagulation activation, increased levels of plasma D-dimer, fibrinogen, thrombin-antithrombin, prothrombin fragment 1+2, and antithrombin-III were significantly associated with AF (SMD [95% CI]: 1.82[1.38–2.26], 0.72[0.55–0.89], 0.42[0.13–0.72], 1.00[0.00–1.99] and 1.38[0.16–2.60], respectively). For fibrinolytic function, tissue-type plasminogen activator and plasminogen activator inhibitor-1 were significantly increased in AF cases compared with controls (SMD [95% CI]: 0.86[0.04–1.67] and 0.87[0.28–1.47], respectively) but the associations became nonsignificant after performing subgroup analysis by anticoagulants treatment status. For endothelial function, increased von Willebrand factor was significantly associated with AF (SMD, 0.79; 95% CI, 0.55–0.99); however, no association was observed for soluble thrombomodulin (SMD, 0.60; 95% CI, -0.13–1.33).
Conclusions
Increased circulating hemostatic factors (PF-4, BTG, P-selectin, D-dimer, fibrinogen, TAT, F1+2, AT- III, and vWF) are significantly associated with AF. Future research is necessary to elucidate the precise mechanism of the prothrombotic state and how hemostatic markers promote thromboembolism in AF.

Introduction
The prevalence of atrial fibrillation (AF) is estimated to be 0.4% to 1.0% in the general population and is increasing [1]. It confers a high risk of mortality and morbidity from strokes and thromboembolisms [2]. The pathophysiological mechanism that leads to strokes and thromboembolisms in AF is multifactorial. Stasis in the poorly contractile left atrium is partially responsible, but there is increasing evidence that indicates the presence of a prothrombotic or hypercoagulable state in AF [3].

Over 150 years ago, Rudolf Virchow proposed a triad of events that are necessary for thrombus formation, including blood flow abnormalities, blood vessel wall abnormalities and blood constituents [4]. In the 21st century, Virchow’s triad has been revised as follows: endothelial or endocardial damage or dysfunction (and related structural abnormal changes); abnormal blood stasis; and abnormal hemostasis, platelets, and fibrinolysis [2, 3]. An increasing number of studies have been performed to delineate hemostatic function in AF. The abnormalities observed in AF primarily include abnormal endothelial function, platelet and coagulation activation, and abnormal fibrinolysis. For coagulation and platelet activation, some studies have demonstrated that coagulation and platelet activation markers were elevated in AF [5–7]. However, other studies have failed to demonstrate these associations [8, 9]. The fibrinolytic system is usually activated when a thrombus is formed, but it is still controversial whether a hyperfibrinolytic or hypofibrinolytic state is related to AF [10–12]. It is also unclear whether endothelial dysfunction, indicated by circulating markers of endothelial origin, is associated with AF [13, 14].

Identifying the specific hemostatic markers that are associated with AF is important for understanding AF etiology, development and prognosis. Therefore, we conducted a meta-analysis to evaluate the associations between hemostatic markers (including markers of platelet activation, coagulation activation, fibrinolytic function, and endothelial function) and AF.

Methods
Search Strategy
This meta-analysis was performed according to the guidelines presented in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [15]. We used electronic database and manual searches to identify relevant studies. The PubMed, EMBASE, Web of Science, and Chinese Biomedical Literature (CBM) databases were systematically searched for studies published up to July 2013 using a web-based search engine. The search terms used to identify relevant studies were “platelet”, “platelet factor-4”, “β-thromboglobulin”, “P-selectin”, “D-dimer”, “fibrinogen”, “prothrombin fragment 1+2”, “thrombin-antithrombin”, “anti-thrombin-III”, “a2-antiplasmin”, “fibrinopeptide A”, “tissue-type plasminogen activator”, “urokinase-type plasminogen activator”, “plasminogen activator inhibitor”, “plasmin-antiplasmin complex”, “von Willebrand factor” or “soluble thrombomodulin”, and “atrial fibrillation”. We also manually searched journals and the reference lists of all retrieved articles. Additionally,
relevant review articles were also cross-referenced. The literature retrieval was performed in duplication by two independent reviewers (N.W. and S. T.).

**Study selection**

Human studies, regardless of sample size, were included if they met the following criteria: (1) the study design was a case-control study (retrospective or nested case-control) or cohort study (retrospective or prospective cohort study) and (2) the study investigated the association between hemostatic markers (including markers of endothelial function, platelet activation, coagulation activation, and fibrinolytic function) and AF.

When multiple publications were based on the same or overlapping data, we used the most recent or largest population as recommended by Little et al [16]. The number of participants in groups, mean hemostatic marker levels and standard deviations (SD) had to be provided or could be converted from the median and range data or determined from figures. For studies that did not have adequate data, we contacted the authors to obtain the unpublished results; if the author was not able to provide the necessary data, these studies were excluded. Certain hemostatic markers, such as urokinase-type plasminogen activator, a2-antiplasmin, plasmin-antiplasmin complex and fibrinopeptide A, were investigated in less than two studies and were also excluded from this meta-analysis.

**Quality Assessment**

Two reviewers (N.W. and S. T.) independently assessed the study quality using the primary criteria for nonrandomized studies described in the Newcastle-Ottawa scale [17]. A "score system" was developed based on the Newcastle-Ottawa criteria (S1 Table). The total scores ranged from 0 (worst) to 9 (best) for case-control or cohort studies. A score consensus was reached after discussion to resolve any disagreements.

**Data Extraction**

Using standard data extraction forms, two reviewers (N.W. and Y.X.) extracted data from the relevant studies. We extracted publication information (first author’s name, publication year, country, study design), participant characteristics (mean age of participants, gender, sample size, type of study e.g., case/control, anticoagulants treatment status, coexistent cardiovascular disease and risk factors), the type of AF and hemostatic marker levels (the mean and SD of each group). Any disagreements were resolved by consensus with a third reviewer (L.Z.).

If the study provided the medians and ranges instead of the means and SDs, we imputed the means and SDs using the method developed by Hozo et al [18]. For studies that reported interquartile ranges instead of the range, we multiplied the difference between the median, upper and lower ends of the interquartile range by 2 and added or subtracted the product from the median to estimate the lower and upper values of the range as described by Liu et al [19]. For studies that provided only figures and when the exact data could not be obtained after contacting the authors, we used the program Engauge Digitizer 4.1 (M. Mitchell, Engauge Digitizer, http://digitizer.sourceforge.net) to read the exact means and SDs from the figures. This program was able to read the exact values by digitizing the data points in an image file after manually setting the axis coordinates.

**Statistical analysis**

The standardized mean difference (SMD) was used as a summary statistic in the meta-analysis. SMD is the difference in mean outcomes between groups divided by the standard deviation of
the outcome among participants. The SMD method is commonly used when a variety of methods and units are used to measure hemostatic marker levels among different studies. In this circumstance, it was necessary to standardize the results of the studies to a uniform scale before they were able to be combined. The statistical heterogeneity across studies was assessed using the $I^2$ statistic, which describes the proportion of total variation across studies that is due to heterogeneity rather than chance [20]. An $I^2 \geq 50\%$ suggests that there is significant heterogeneity between studies. The SMD was pooled using a random effects model to manage heterogeneity when the heterogeneity was significant ($I^2 \geq 50\%$); otherwise, a fixed effects model was applied. We evaluated potential publication bias using funnel plots and Begg’s tests [21].

A weighted random-effect meta-regression analysis was performed to examine potential sources of heterogeneity and potential confounding factors. The weight for each trial was equal to the inverse of the sum of the within trial variance and the residual between trial variance. The true effect of each included study was treated as random-effect, and the true effects of included studies are a random sample of the relevant distribution of true effects [22]. Based on prior research [7, 23–25], we examined specific between-study characteristics which might influence the level of hemostatic markers and attribute to heterogeneity, including study design (case-control study vs. cohort study), publication year (before 2000 vs. after 2000), mean age (under 60 years vs. at least 60 years), type of AF (paroxysmal AF which is defined as arrhythmia terminates spontaneously vs. persistent AF which refers to AF sustained beyond 7 days and permanent AF denoting long-standing AF which lasts more than 1 year [1]), cardiovascular disease and risk factors, including hypertension, coronary artery disease, cerebrovascular accidents, diabetes mellitus, smoking and gender (the ratio of the proportion of subjects who have the investigated factors between AF patients and controls). We performed univariate meta-regressions and these factors were entered into the meta-regression model separately. A multivariate meta-regression was also conducted when more than one characteristic was significantly ($P < 0.05$) in univariate model. A subgroup analysis was performed by categorical variables which were significant in the univariate meta-regression model to explore how these factors influenced the level of hemostatic markers. Considering anticoagulant treatment had great impact on levels of hemostatic markers, we also carried out a subgroup analysis by anticoagulants treatment status as follows: Subgroup 1, there was significant difference in the proportion of subjects received anticoagulants between AF patients and controls; Subgroup 2, no patient received anticoagulants in both groups; Subgroup 3, all participants were anticoagulated in both groups; Subgroup 4, there was no significant difference in the proportion of anticoagulation treatment in both groups (excluding the Subgroup 2 and 3); Subgroup 5, anticoagulation information was not available in both groups. The significance level for all analyses was set at $P < 0.05$. Statistical analyses were performed using the STATA software package (version 11.0, College Station, TX).

Results

Description of studies

A total of 661 records were retrieved after the primary literature search. After screening the titles and abstracts, 531 studies were excluded; 106 potentially relevant full-text articles were reviewed, and 59 studies were included in the meta-analysis (Fig 1). Of the 59 included studies, 35 studies investigated the association between platelet activation markers and AF, with a total of 2730 cases and 2371 controls [5–9, 13, 23, 24, 26–52]. There were 48 studies examining the association between coagulation activation markers and AF, including 5412 AF cases and 29292 controls [5, 7, 8, 11–14, 24, 25, 27, 29, 31, 33, 34, 36–39, 41–43, 45–48, 50–72]. A total of 11 studies...
investigated the association between fibrinolytic function markers and AF, with 631 patients and 6558 controls [11–13, 31, 45, 50, 59, 61, 63, 67, 72]. Finally, 19 studies examined the association between endothelial function markers and AF, with 2502 cases and 15289 controls [7, 13, 14, 24, 27, 31, 34, 37, 41–43, 46, 50–52, 57, 59, 64, 71]. The mean age of AF patients ranged from 37.0 to 81.5. All case-control and cohort studies had a quality score of at least 6 (S2 Table).

**Platelet activation**

The meta-analysis of 14 studies determined that platelet count was not significantly different between AF cases and controls with a pooled SMD -0.29 (95% CI, -0.59–0.02; P = 0.066) (Fig 2A). Mean platelet volume (MPV), circulating levels of platelet factor-4 (PF-4), β-thromboglobulin (BTG) and P-selectin were higher in AF cases than controls, with a pooled SMD of 0.92 (95% CI, 0.12–1.73; P = 0.025), 1.72 (95% CI, 0.96–2.49; P<0.001), 1.61 (95% CI, 1.03–2.19; P<0.001), and 0.50 (95% CI, 0.23–0.77; P<0.001), respectively (Fig 2B–2E).

There was significant heterogeneity for studies investigating platelet activation markers, with an I² above 90% (Table 1). In the univariate meta-regression analyses, three factors were associated with heterogeneity for platelet count: type of AF, hypertension, and coronary artery disease. The multivariate meta-regression could not be performed for platelet count because the limited number of included studies. We did not find an association between all the potential factors and heterogeneity for MPV, PF-4, BTG and P-selectin (S3 Table). A subgroup analysis

![Flow diagram of the literature search and study selection.](doi:10.1371/journal.pone.0124716.g001)
Fig 2. Association between platelet activation markers and AF. A. platelet count and AF; B. Mean platelet volume and AF; C. Platelet factor-4 and AF; D. β-thromboglobulin and AF; E. P-selectin and AF. Forest plots of SMD and overall SMD with 95% CI between AF cases and controls. Black diamonds indicate the SMD, with the size of the square inversely proportional to its variance, and horizontal lines represent the 95% CI. The pooled results are indicated by the black hollow diamond. AF, atrial fibrillation; MPV, mean platelet volume; PF-4, platelet factor-4; BTG, β-thromboglobulin; PAF, paroxysmal AF; PeAF, persistent AF; PfAF, permanent AF; CAF, chronic AF; SMD, standardized mean difference.

doi:10.1371/journal.pone.0124716.g002
indicated that there was no significant association between platelet count and paroxysmal or permanent AF (S1 Fig). The heterogeneity was significantly reduced among the three paroxysmal AF studies with an $I^2 = 49.3\%$ ($P = 0.139$) and two permanent AF studies with an $I^2 = 0.0\%$ ($P = 0.895$) (S1 Fig). The results of univariate meta-analysis were not materially altered for platelet count, PF-4, BTG and P-selectin after grouping by anticoagulants treatment status (data not shown). However, the association between MPV and AF vanished in studies with and without different proportion of people anticoagulated in two compared groups (S2 Fig).

### Coagulation activation

Coagulation activation markers, including plasma D-dimer, fibrinogen, prothrombin fragment 1+2 (F1+2), and antithrombin—antithrombin; F1+2, prothrombin fragments 1+2; AT-III, Antithrombin III; tPA, tissue plasminogen activator; PAI-1, plasminogen activator inhibitor-1; vWf, vonWillebrand factor; sTM, soluble thrombomodulin; SMD, standardized mean difference; CI, confidence interval.

doi:10.1371journal.pone.0124716.t001

| Hemostatic marker | Pooled SMD with 95% CI | Test for overall effect (P value) | Heterogeneity |
|-------------------|------------------------|----------------------------------|---------------|
|                   |                        |                                  | Q-test (P value) | $I^2$ (%) |
| **Platelet activation** |                        |                                  |               |         |
| Platelet count    | -0.29 (-0.59–0.02)    | 0.066                            | <0.001        | 90.2    |
| MPV               | 0.92 (0.12–1.73)      | 0.025                            | <0.001        | 97.3    |
| PF-4              | 1.72 (0.96–2.49)      | <0.001                           | <0.001        | 95.5    |
| BTG               | 1.61 (1.03–2.19)      | <0.001                           | <0.001        | 96.0    |
| P-selectin        | 0.50 (0.23–0.77)      | <0.001                           | <0.001        | 90.0    |
| **Coagulation activation** |                        |                                  |               |         |
| D-dimer           | 1.82 (1.38–2.26)      | <0.001                           | <0.001        | 96.6    |
| Fibrinogen        | 0.72 (0.55–0.89)      | <0.001                           | <0.001        | 94.0    |
| TAT               | 0.42 (0.13–0.72)      | 0.005                            | 0.298         | 18.3    |
| F1+2              | 1.00 (0.00–1.99)      | 0.049                            | <0.001        | 97.7    |
| AT-III            | 1.38 (0.16–2.60)      | 0.027                            | <0.001        | 95.6    |
| **Fibrinolytic function** |                        |                                  |               |         |
| tPA               | 0.86 (0.04, 1.67)     | 0.041                            | <0.001        | 96.7    |
| PAI-1             | 0.87 (0.28–1.47)      | 0.004                            | <0.001        | 96.3    |
| **Endothelial function** |                        |                                  |               |         |
| vWf               | 0.79 (0.60–0.99)      | <0.001                           | <0.001        | 90.1    |
| sTM               | 0.60 (-0.13–1.33)     | 0.107                            | <0.001        | 91.6    |

AF, atrial fibrillation; MPV, mean platelet volume; PF-4, platelet factor 4; BTG, β-thromboglobulin; P-sel, P-selectin; Fib, fibrinogen; TAT, thrombin—antithrombin; F1+2, prothrombin fragments 1+2; AT-III, Antithrombin III; tPA, tissue plasminogen activator; PAI-1, plasminogen activator inhibitor-1; vWf, vonWillebrand factor; sTM, soluble thrombomodulin; SMD, standardized mean difference; CI, confidence interval.

There was significant heterogeneity between the studies investigating D-dimer, fibrinogen, F1+2, and AT-III (Table 1). According to the univariate meta-regression results, the type of AF was associated with heterogeneity for D-dimer. The publication year and gender were associated with heterogeneity for fibrinogen (S3 Table), and multivariate meta-analysis showed similar result with univariate model, indicating publication year and gender were significantly associated with heterogeneity for fibrinogen. The proportion of between-study variance explained by these two covariates was 41.26% (S4 Table). A subgroup analysis demonstrated that the association between D-dimer and AF was significant in paroxysmal, persistent and permanent AF.
### Hemostatic Markers and Atrial Fibrillation

#### Hemostatic Markers and Atrial Fibrillation

**A)**

| Study ID | SMD (95% CI) | Weight |
|---------|-------------|--------|
| A       |             |        |
| B       |             |        |
| C       |             |        |

**B)**

| Study ID | SMD (95% CI) | Weight |
|---------|-------------|--------|
|          |             |        |

**C)**

| ID    | SMD (95% CI) | Weight |
|-------|-------------|--------|
|       |             |        |

**D)**

| ID    | SMD (95% CI) | Weight |
|-------|-------------|--------|
|       |             |        |

**E)**

| ID     | SMD (95% CI) | Weight |
|--------|-------------|--------|
|        |             |        |

**Note:** Weights are from random-effects analysis.

---

**Fig 3.** Association between coagulation activation markers and AF. A. D-dimer and AF; B. fibrinogen and AF; C. Thrombin-antithrombin and AF; D. Prothrombin fragment 1+2 and AF; E. Antithrombin-III and AF. Forest plots of SMD and overall SMD with 95% CI between AF cases and controls. Black diamonds indicate the SMD, with the size of the square inversely proportional to its variance, and horizontal lines represent the 95% CI. The pooled results are indicated by the black hollow diamond. AF, atrial fibrillation; TAT, thrombin-antithrombin; F1+2, prothrombin fragment 1+2; AT-III, antithrombin-III; PAF, paroxysmal AF; PeAF, persistent AF; PtAF, permanent AF; CAF, chronic AF; aAF, acute AF; SMD, standardized mean difference.

doi:10.1371/journal.pone.0124716.g003
After grouping by publication year, the associations between fibrinogen and AF were significant for studies published after 2000 and those published before 2000 (S4 Fig). Results of subgroup analyses by anticoagulants treatment status for D-dimer, fibrinogen, TAT, F1+2 and AT-III were consistent with the overall effects (data not shown). A meta-regression analysis was not performed for TAT, F1+2, and AT-III because of a limited number of studies.

**Fibrinolytic function**

The indicators of fibrinolytic function included in this meta-analysis were tissue-type plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1). A meta-analysis of 9 studies for tPA and 11 studies for PAI-1 determined that both markers were significantly increased in AF cases compared with controls, with a pooled SMD of 0.86 (95% CI, 0.04–1.67; \( P = 0.041 \)) and 0.87 (95% CI, 0.28–1.47; \( P = 0.004 \)), respectively (Fig 4A and 4B). A subgroup analysis stratified by anticoagulants treatment status was performed. For both tPA and PAI-1, the associations became nonsignificant for all subgroups (S5 Fig, S6 Fig). There was significant heterogeneity among the studies investigating tPA and PAI-1, with an \( I^2 \) of approximately 96% (Table 1). However, univariate meta-regression analyses did not identify any potential sources of heterogeneity for tPA and PAI-1 (S3 Table).

**Endothelial function**

According to a meta-analysis of 19 studies, plasma von Willebrand factor (vWF) was significantly elevated in AF patients compared with controls, with a pooled SMD of 0.79 (95% CI, 0.60–0.99; \( P < 0.001 \)) (Fig 5A). No significant association was observed between soluble thrombomodulin (sTM) and AF (pooled SMD 0.60; 95% CI, −0.13–1.33; \( P = 0.107 \)) (Fig 5B). A univariate meta-regression analysis indicated that study design and gender had a significant effect on the level of vWF (S3 Table). However, the test for multivariate model was borderline significant (\( P = 0.0505 \)) (S4 Table). A subgroup analysis determined that the associations between vWF and AF were significant for both case-control and cohort studies (S7 Fig). The results of subgroup analyses after grouping by anticoagulants treatment status were materially consistent with overall effects (S8 Fig).

**Discussion**

This meta-analysis summarized the evidence to date regarding the association between a series of hemostatic markers and AF. Our results demonstrated that increased circulating PF-4, BTG, P-selectin, D-dimer, fibrinogen, TAT, F1+2, AT-III, and vWF levels were significantly associated with AF.

Platelet and coagulation activation, fibrinolytic dysfunction, and endothelial damage are four major components of the hemostatic mechanism. Several studies have demonstrated that certain hemostatic markers are associated with AF, but these associations remain controversial [4, 73]. Our meta-analysis determined that circulating PF-4, BTG and P-selectin levels were significantly associated with AF, reflecting an activated platelet state. Coagulation activation markers, such as plasma D-dimer, fibrinogen, TAT, F1+2, and AT-III, were significantly increased in AF patients. Finally, the endothelial dysfunction marker vWF was elevated in AF patients.

The exact mechanism of the association between the abnormal levels of hemostatic markers and AF is unclear. Whether abnormal level of hemostatic markers is a consequence of AF or the presence of alteration in hemostatic markers promotes AF development is still under debate. Accumulative proofs have implied that both mechanisms may interrelate, which means that hemostatic markers are not only a consequence but also a cause. Lip proposed that AF can confer a hypercoagulable state as early as 1995 [74]. Researchers have artificially induced AF in
Fig 4. Association between fibrinolytic function makers and AF. A. Tissue-type plasminogen activator and AF; B. Plasminogen activator inhibitor-1 and AF. Forest plots of SMD and overall SMD with 95% CI between AF cases and controls. Black diamonds indicate the SMD, with the size of the square inversely proportional to its variance, and horizontal lines represent the 95% CI. The pooled results are indicated by the black hollow diamond. AF, atrial fibrillation; tPA, tissue-type plasminogen activator; PAI-1, plasminogen activator inhibitor-1; SMD, standardized mean difference.

doi:10.1371/journal.pone.0124716.g004
Table 2. Association between endothelial function markers and AF.

| Study ID | SMD (95% CI) | Weight |
|----------|--------------|---------|
| Fa R (2010) | 0.32 (0.02, 0.62) | 4.23 |
| Hou J (disease control) (2010) | 0.16 (-0.38, 0.71) | 3.43 |
| Hou J (healthy control) (2010) | 0.51 (-0.05, 1.06) | 3.40 |
| Blann (2007) | 0.90 (0.42, 1.38) | 3.66 |
| Topaloglu (disease control) (2007) | 0.32 (-0.27, 0.92) | 3.26 |
| Topaloglu (healthy control) (2007) | 1.24 (0.54, 1.94) | 2.92 |
| Marin F (aAF) (2004) | 1.44 (0.80, 2.08) | 3.12 |
| Marin F (CAF) (2004) | 1.38 (0.93, 1.23) | 3.07 |
| Conway DS (PaAF) (2004) | 0.28 (-0.98, 0.65) | 4.05 |
| Hatzinikolaou – Kotsakou (PaAF) (2004) | 0.98 (0.27, 1.68) | 2.90 |
| Hatzinikolaou – Kotsakou (PaAF) (2004) | 1.22 (0.48, 1.95) | 2.80 |
| Hatzinikolaou – Kotsakou (PaAF) (2004) | 2.91 (1.97, 3.85) | 2.23 |
| Conway DS (2003) | 0.19 (-0.00, 0.38) | 4.52 |
| Li–Saw–Hee FL (PaAF) (2001) | 0.90 (0.27, 1.53) | 3.14 |
| Li–Saw–Hee FL (PaAF) (2001) | 0.18 (-0.42, 0.78) | 3.24 |
| Li–Saw–Hee FL (PaAF) (2001) | 1.03 (0.39, 1.67) | 3.11 |
| Feng D (2001) | 0.11 (-0.21, 0.44) | 4.17 |
| Mondillo S (2000) | 1.81 (1.28, 2.33) | 3.50 |
| Li–Saw–Hee FL (2000) | 1.12 (0.72, 1.52) | 3.93 |
| Li–Saw–Hee FL (1999) | 1.69 (1.04, 2.34) | 3.08 |
| Kahn (1997) | 0.50 (0.05, 0.95) | 3.74 |
| Lip GY (1995) | 2.14 (1.82, 2.46) | 4.17 |
| Gustafsson C (with stroke) (1990) | 0.87 (0.31, 1.43) | 3.38 |
| Gustafsson C (without stroke) (1990) | 0.81 (0.25, 1.36) | 3.39 |
| Conway DS (2004) | 0.17 (-0.28, 0.63) | 3.74 |
| Heeringa J (2006) | 0.16 (-0.03, 0.35) | 4.52 |
| Alonso A (White) (2010) | 0.31 (0.24, 0.37) | 4.70 |
| Alonso A (African Americans) (2010) | 0.29 (0.16, 0.43) | 4.62 |
| Overall (I-squared = 91.6%, p = 0.000) | 0.79 (0.60, 0.99) | 100.00 |

**Fig 5. Association between endothelial function markers and AF.** A. Von Willebrand factor and AF; B. Soluble thrombomodulin and AF. Forest plots of SMD and overall SMD with 95% CI between AF cases and controls. Black diamonds indicate the SMD, with the size of the square inversely proportional to its variance, and horizontal lines represent the 95% CI. The pooled results are indicated by the black hollow diamond. AF, atrial fibrillation; vWF, von Willebrand factor; sTM, soluble thrombomodulin; PAF, paroxysmal AF; PeAF, persistent AF; PtAF, permanent AF; CAF, chronic AF; aAF, acute AF; SMD, standardized mean difference.

doi:10.1371/journal.pone.0124716.g005
patients and have determined that local cardiac platelet activation could be caused by artificially induced AF [75]. The exact mechanism driving the prothrombotic state in AF is unclear. One of the explanations is that the poorly contractile left atrium in AF leads to increased stasis within the atrium, probably activating multiple hemostatic markers, especially the interaction between erythrocytes and fibrinogen [2]. Several other hypotheses have been proposed, such as inflammation, release of growth factors, abnormal changes in extracellular matrix turnover, and dysfunction in the renin-angiotensin-aldosterone system (RAAS) [3]. The development and maintenance of AF requires an initiating factor (trigger) and an appropriate substrate. Electrophysiological and structural remodeling of the atria provides the substrate [76]. A significant amount of information has demonstrated that inflammation is interrelated with atrial remodeling and related to AF risk [77]. Additionally, inflammation has been associated with endothelial dysfunction, platelet and coagulation activation [78]. The exact mechanism for the interactions between the hemostatic system, inflammation and AF risk needs to be further investigated. Growth factor, in particular vascular endothelial growth factor (VEGF) is able to stimulate tissue factor production which could be one of the driving forces of prothrombotic state in AF [79]. Extracellular matrix turnover plays an important role in atrial remodeling and also may be responsible for prothrombotic state by causing blood stasis and damaging endocardium [3]. Angiotensin II which is a critical factor in RAAS has been shown to increase the release of various proinflammatory cytokines such as interleukin 6 and tumor necrosis factor α [80]. Thus, RAAS may contribute to prothrombotic state through inflammation. On the other hand, the innate alteration in some hemostatic markers at baseline may increase the risk of AF development in the future as suggested by some cohort studies [69–72]. However, the relevant large cohort studies are scarce and a synthetic conclusion is difficult to be drawn.

Additionally, hemostatic markers can be altered by antithrombotic medications. A study has demonstrated that after receiving anticoagulation, the levels of D-dimer and F1+2 in AF patients were lowered [64]. Therefore, we carried out a subgroup analysis by anticoagulants treatment status in our study. We found there was no significant association between MPV, tPA, PAI-1 and AF in participants receiving no anticoagulants and also in studies with different proportion of people anticoagulated in two compared groups. This result was in contrary to overall effects. It indicated anticoagulants had a great impact on these markers and acted as an important confounding factor. One of the main contributors of the abnormal levels of hemostatic markers, namely stasis caused by poorly contractile left atrium in AF may be responsible for the vanishment of association after performing subgroup analysis stratified by anticoagulants treatment status.

AF is sometimes complicated by other cardiovascular diseases, and hemostatic markers are known to be influenced by these comorbidities. Whether hemostatic markers are increased due to AF itself or are coexisting cardiovascular risk factors remains a matter of debate [2]. Feng et al [59] discovered that the association of fibrinogen, vWF, tPA and PAI-1 and AF became nonsignificant after stratifying according to cardiovascular disease status. We tried to explore the influence of comorbidities by taking hypertension, coronary artery disease, cerebrovascular accidents and diabetes mellitus into meta-regression model. However, we only found hypertension and coronary artery disease were significantly associated with level of platelet count.

There is also a strong association between AF and the risk of thromboembolic stroke, although the mechanism for this increased risk has not been fully determined. The pathogenesis is multifactorial and stasis in a poorly contractile left atrium is partially responsible [3]. In addition, some studies determined that MPV, vWF, D-dimer and tPA were able to effectively predict subsequent thromboembolic events in patients with AF [81–83]. Considering the predictive role of these hemostatic markers for thromboembolic events, the inclusion of these markers in thromboembolic risk prediction models for the identification of “high risk” or “true low risk” subjects is worth attempting.
To the best of our knowledge, this is the first systematic and comprehensive meta-analysis examining the associations between a series of hemostatic markers and AF. Due to the currently high incidence of AF and subsequent thromboembolic events, identifying of biological markers that can predict AF risk and hypercoagulable propensity has important clinical implications. However, several limitations of this study should be considered when interpreting our results. High heterogeneity exists among studies. Therefore, we performed a meta-regression analysis to identify potential sources of heterogeneity; gender, type of AF, and comorbidities may explain a portion of this heterogeneity. However, not all of the relevant covariates, such as heart failure and inflammatory factors, are available for each study included in our meta-regression. Therefore, the heterogeneity and unknown confounders may still influence true associations. Secondly, observational studies especially case-control studies could only determine whether there was an excess risk of adverse outcome in association with biomarkers. Verifying causality requires more high-quality, large sample, and more stringent evidence. Our study as a systematic review and meta-analysis summarized the evidences in this field and could provide useful clues and generate initial data for future studies. Finally, statistical tests suggested that there might be publication bias for studies examining BTG, D-dimer, fibrinogen, AT-III and vWF (S9 Fig).

Conclusion

In conclusion, our meta-analysis demonstrated that elevated circulating hemostatic markers (PF-4, BTG, P-selectin, D-dimer, fibrinogen, TAT, F1+2, AT-III, and vWF) were associated with AF. Our findings provide useful clues and evidences for future study to elucidate the precise mechanism of the prothrombotic state and the role of hemostatic markers in promoting thromboembolism in AF patients.

Supporting Information

S1 Checklist. PRISMA Checklist. (DOC)

S1 Fig. Association of platelet count with AF by type of AF. Black diamond indicates the SMD, with the size of the square inversely proportional to its variance, and horizontal lines represent 95% CI. The pooled results are indicated by the black hollow diamond. AF, atrial fibrillation; PAF, paroxysmal AF; PtAF, permanent AF; SMD, standardized mean difference; CI, confidence interval. (JPG)

S2 Fig. Association of mean platelet volume with AF by anticoagulants treatment status. Black diamond indicates the SMD, with the size of the square inversely proportional to its variance, and horizontal lines represent 95% CI. The pooled results are indicated by the black hollow diamond. AF, atrial fibrillation; MPV, mean platelet volume; SMD, standardized mean difference; CI, confidence interval; Subgroup 1, there was significant difference in the proportion of subjects received anticoagulants between AF patients and controls; Subgroup 4, there was no significant difference in the proportion of anticoagulation treatment in both groups (excluding no patient or all patients received anticoagulants in both groups). (JPG)

S3 Fig. Association of D-dimer with AF by type of AF. Black diamond indicates the SMD, with the size of the square inversely proportional to its variance, and horizontal lines represent 95% CI. The pooled results are indicated by the black hollow diamond. AF, atrial fibrillation; PAF, paroxysmal AF; PtAF, permanent AF; SMD, standardized mean difference; CI, confidence interval. (JPG)
S4 Fig. Association of fibrinogen with AF by publication year. Black diamond indicates the SMD, with the size of the square inversely proportional to its variance, and horizontal lines represent 95% CI. The pooled results are indicated by the black hollow diamond. AF, atrial fibrillation; \( \geq 2000 \), publication year after 2000; \(< 2000\), publication year before 2000; SMD, standardized mean difference; CI, confidence interval.

S5 Fig. Association of tissue-type plasminogen activator with AF by anticoagulants treatment status. Black diamond indicates the SMD, with the size of the square inversely proportional to its variance, and horizontal lines represent 95% CI. The pooled results are indicated by the black hollow diamond. AF, atrial fibrillation; tPA, tissue-type plasminogen activator; SMD, standardized mean difference; CI, confidence interval; Subgroup 1, there was significant difference in the proportion of subjects received anticoagulants between AF patients and controls; Subgroup 2, no patient received anticoagulants in both groups; Subgroup 5, anticoagulation information was not available in both groups.

S6 Fig. Association of plasminogen activator inhibitor-1 with AF by anticoagulants treatment status. Black diamond indicates the SMD, with the size of the square inversely proportional to its variance, and horizontal lines represent 95% CI. The pooled results are indicated by the black hollow diamond. AF, atrial fibrillation; PAI-1, plasminogen activator inhibitor-1; SMD, standardized mean difference; CI, confidence interval; Subgroup 1, there was significant difference in the proportion of subjects received anticoagulants between AF patients and controls; Subgroup 2, no patient received anticoagulants in both groups; Subgroup 5, anticoagulation information was not available in both groups.

S7 Fig. Association of vonWillebrand factor with AF by study design. Black diamond indicates the SMD, with the size of the square inversely proportional to its variance, and horizontal lines represent 95% CI. The pooled results are indicated by the black hollow diamond. vWF, vonWillebrand factor; AF, atrial fibrillation; PAF, paroxysmal AF; PeAF, persistent AF; PtAF, permanent AF; aAF, acute AF; CAF, chronic AF; SMD, standardized mean difference; CI, confidence interval.

S8 Fig. Association of vonWillebrand factor with AF by anticoagulants treatment status. Black diamond indicates the SMD, with the size of the square inversely proportional to its variance, and horizontal lines represent 95% CI. The pooled results are indicated by the black hollow diamond. AF, atrial fibrillation; PAF, paroxysmal AF; PeAF, persistent AF; PtAF, permanent AF; aAF, acute AF; CAF, chronic AF; SMD, standardized mean difference; CI, confidence interval; Subgroup 1, there was significant difference in the proportion of subjects received anticoagulants between AF patients and controls; Subgroup 2, no patient received anticoagulants in both groups; Subgroup 4, there was no significant difference in the proportion of anticoagulation treatment in both groups; Subgroup 5, anticoagulation information was not available in both groups.

S9 Fig. Funnel plot analysis to detect publication bias. Each point represents a separate study for the indicated association. P values were calculated by Begg’s test. A. Platelet count and AF \( (P = 0.484) \); B. MPV and AF \( (P = 0.462) \); C. PF-4 and AF \( (P = 0.584) \); D. BTG and AF \( (P = 0.042) \); E. P-selectin and AF \( (P = 0.535) \); F. D-dimer and AF \( (P = 0.001) \); G. Fibrinogen
and AF (P<0.001); H. TAT and AF (P = 1.000); I. F1+2 and AF (P = 0.466); J. AT-III and AF (P = 0.024); K. tPA and AF (P = 1.000); L. PAI-1 and AF (P = 0.661); M. vWf and AF (P<0.001); N. sTM and AF (P = 0.452).

(DOC)

S1 Table. Quality assessment score scale.

(DOC)

S2 Table. Characteristics of studies included for meta-analysis of association between haemostatic markers and AF.

(DOC)

S3 Table. Univariate meta-regression results for haemostatic markers.

(DOC)

S4 Table. Multivariate meta-regression results for fibrinogen and vWf.

(DOC)

Author Contributions

Conceived and designed the experiments: ZS LZ YL. Performed the experiments: NW ST YX LZ. Analyzed the data: NW LW BX. Contributed reagents/materials/analysis tools: ST. Wrote the paper: NW. Interpreted the data: YZ XM. Edited the manuscript: NW ST YX LW BX YZ XM YL ZS LZ.

References

1. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol. 2011; 57:e101–198. doi:10.1016/j.jacc.2010.09.013 PMID: 21392637

2. Choudhury A, Lip GY. Atrial fibrillation and the hypercoagulable state: from basic science to clinical practice. Pathophysiol Haemost Thromb. 2003; 33:282–289. PMID: 15692230

3. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet. 2009; 373:155–166. doi:10.1016/S0140-6736(09)60040-4 PMID: 19135613

4. Brotman DJ, Deitcher SR, Lip GY, Matzdorff AC. Virchow's triad revisited. South Med J. 2004; 97:213–214. PMID: 14982286

5. Lip GY, Lip PL, Zarifis J, Watson RD, Bareford D, Lowe GD, et al. Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin. Circulation. 1996; 94:425–431. PMID: 8759084

6. Colkesen Y, Acil T, Abayli B, Yigit F, Katircibasi T, Kocum T, et al. Mean platelet volume is elevated during paroxysmal atrial fibrillation: a marker of increased platelet activation? Blood Coagul Fibrinolysis. 2008; 19:411–414. doi:10.1097/MBC.0b013e3283049687 PMID: 18600091

7. Fu R, Wu S, Wu P, Qiu J. A study of blood soluble P-selectin, fibrinogen, and von Willebrand factor levels in idiopathic and lone atrial fibrillation. Europace. 2011; 13:31–36. doi:10.1093/europace/euq346 PMID: 20852292

8. Sohara H, Miyahara K. Effect of atrial fibrillation on the fibrino-coagulation system—study in patients with paroxysmal atrial fibrillation. Jpn Circ J. 1994; 58:821–826. PMID: 7807680

9. Choudhury A, Chung I, Panja N, Patel J, Lip GY. Soluble CD40 ligand, platelet surface CD40 ligand, and total platelet CD40 ligand in atrial fibrillation: relationship to soluble P-selectin, stroke risk factors, and risk factor intervention. Chest. 2008; 134:574–581. doi:10.1378/chest.07-2745 PMID: 18641098

10. Marin F, Reidan V, Lip GY. Fibrinolytic function and atrial fibrillation. Thromb Res. 2003; 109:233–240. PMID: 12618244

11. Reidan V, Marin F, Marco P, Martinez JG, Calatayud R, Sogorb F. Hypofibrinolysis in atrial fibrillation. Am Heart J. 1998; 136:956–960. PMID: 9942006
12. Wang TD, Chen WJ, Su SS, Su TC, Chen MF, Liau CS, et al. Increased levels of tissue plasminogen activator antigen and factor VIII activity in nonvalvular atrial fibrillation: relation to predictors of thromboembolism. J Cardiovasc Electrophysiol. 2001; 12:877–884. PMID: 11523531

13. Mondillo S, Sabatini L, Agricola E, Ammaturo T, Guerrini F, Barbati R, et al. Correlation between left atrial size, prothrombotic state and markers of endothelial dysfunction in patients with lone chronic non-rheumatic atrial fibrillation. Int J Cardiol. 2000; 75:227–232. PMID: 11077138

14. Marin F, Roldan V, Climent VE, Ibanez A, Garcia A, Marco P, et al. Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation. Heart. 2004; 90:1162–1166. PMID: 15367514

15. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009; 62:e1–34. doi: 10.1016/j.jclinepi.2009.06.006 PMID: 19631507

16. Little J, Bradley L, Bray MS, Clyne M, Dorman J, Ellsworth DL, et al. Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol. 2002; 156:300–310. PMID: 12181099

17. Wells GA SB, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. 2011. Available: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

18. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005; 5:13. PMID: 15840177

19. Liu T, Li G, Li L, Korantzopoulos P. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol. 2007; 49:1642–1648. PMID: 17433956

20. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327:557–560. PMID: 12958120

21. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50:1088–1101. PMID: 7786990

22. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med. 1999; 18:2693–2708. PMID: 10521860

23. Feng C, Mei W, Luo C, Long M, Hu X, Huang Y, et al. Relationship between mean platelet volume and coronary blood flow in patients with atrial fibrillation. Heart Lung Circ. 2013; 22:43–49. doi: 10.1016/j.hlcc.2012.08.052 PMID: 22981758

24. Hou J, Liang Y, Gai X, Zhang H, Yang X, Lan X, et al. The impact of acute atrial fibrillation on the prothrombotic state in patients with essential hypertension. Clin Biochem. 2010; 43:1212–1215. doi: 10.1016/j.clinbiochem.2010.07.013 PMID: 20655891

25. Turgut N, Akdemir O, Turgut B, Demir M, Ekuklu G, Vural O, et al. Hypercoagulopathy in stroke patients with nonvalvular atrial fibrillation: hematologic and cardiologic investigations. Clin Appl Thromb Hemost. 2006; 12:15–20. PMID: 16444430

26. Turgut O, Zorlu A, Kilici F, Cinar Z, Yucel H, Tandogan I, et al. Atrial fibrillation is associated with increased mean platelet volume in patients with type 2 diabetes mellitus. Platelets. 2013; 24:493–497. doi: 10.3109/09537104.2012.725876 PMID: 22994845

27. Acevedo M, Corbalan R, Braun S, Pereira J, Gonzalez I, Navarrete C. Biochemical predictors of cardiac rhythm at 1 year follow-up in patients with non-valvular atrial fibrillation. J Thromb Thrombolysis. 2012; 128: e113–118.

28. Hayashi M, Takeshita K, Inden Y, Ishii H, Cheng XW, Yamamoto K, et al. Platelet activation and induction of tissue factor in acute and chronic atrial fibrillation: involvement of mononuclear cell-platelet interaction. Thromb Res. 2011; 128:e113–118. doi: 10.1016/j.thromres.2011.07.013 PMID: 21824645

29. Alberi S, Angeloni G, Tamburrelli C, Pampuch A, Izzi B, Messano L, et al. Platelet-leukocyte mixed conjugates in patients with atrial fibrillation. Platelets. 2009; 20:235–241. doi: 10.1080/0953710902954370 PMID: 19459131

30. Blann AD, Choudhury A, Freestone B, Patel J, Lip GY. Soluble CD40 ligand and atrial fibrillation: relationship to platelet activation, and endothelial damage/dysfunction. Int J Cardiol. 2008; 127:135–137. PMID: 17351162

31. Topaloglu S, Boyaci A, Ayaz S, Yilmaz S, Yanik O, Ozdemir O, et al. Coagulation, fibrinolytic system activation and endothelial dysfunction in patients with mitral stenosis and sinus rhythm. Angiology. 2007: 58:85–91. PMID: 17351162

32. Yip HK, Chang LT, Sun CK, Yang CH, Hung WC, Hang CL, et al. Platelet activation in patients with chronic nonvalvular atrial fibrillation. Int Heart J. 2006; 47:371–379. PMID: 16823243
33. Inoue H, Nozawa T, Okumura K, Jong-Dae L, Shimizu A, Yano K. Prothrombotic activity is increased in patients with nonvalvular atrial fibrillation and risk factors for embolism. Chest. 2004; 126:687–692. PMID: 15364743

34. Conway DS, Buggins P, Hughes E, Lip GY. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol. 2004; 43:2075–2082. PMID: 15172416

35. Atalar E, Haznedaroglu IC, Acil T, Ozer N, Kiliç H, Ovunc K, et al. Patients with paroxysmal atrial fibrillation but not paroxysmal supraventricular tachycardia display evidence of platelet activation during arrhythmia. Platelets. 2003; 14:407–411. PMID: 14713509

36. Kamath S, Blann AD, Chin BS, Lip GY. Platelet activation, haemorheology and thrombogenesis in acute atrial fibrillation: a comparison with permanent atrial fibrillation. Heart. 2003; 89:1093–1095. PMID: 12923042

37. Conway DS, Heeringa J, Van Der Kuip DA, Chin BS, Hofman A, Witteman JC, et al. Atrial fibrillation and the prothrombotic state in the elderly: the Rotterdam Study. Stroke. 2003; 34:413–417. PMID: 12574552

38. Kamath S, Chin BS, Blann AD, Lip GY. A study of platelet activation in paroxysmal, persistent and permanent atrial fibrillation. Blood Coagul Fibrinolysis. 2002; 13:627–636. PMID: 12439149

39. Kamath S, Blann AD, Chin BS, Lanza F, Aleil B, Cazenave JP, et al. A study of platelet activation in atrial fibrillation and the effects of antithrombotic therapy. Eur Heart J. 2002; 23:1788–1795. PMID: 12419299

40. Kamath S, Blann AD, Caine GJ, Gurney D, Chin BS, Lip GY. Platelet P-selectin levels in relation to plasma soluble P-selectin and beta-thromboglobulin levels in atrial fibrillation. Stroke. 2002; 33:1237–1242. PMID: 11988597

41. Li-Saw-Hee FL, Blann AD, Gurney D, Lip GY. Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function. Eur Heart J. 2001; 22:1741–1747. PMID: 11511124

42. Li-Saw-Hee FL, Blann AD, Lip GY. A cross-sectional and diurnal study of thrombogenesis among patients with chronic atrial fibrillation. J Am Coll Cardiol. 2000; 35:1926–1931. PMID: 10841245

43. Li-Saw-Hee FL, Blann AD, Goldsmith I, Lip GY. Indexes of hypercoagulability measured in peripheral blood reflect levels in intracardiac blood in patients with atrial fibrillation secondary to mitral stenosis. Am J Cardiol. 1999; 83:1206–1209. PMID: 10215285

44. Minamino T, Kitakaze M, Asanuma H, Ueda Y, Kozutsuye Y, Kuzuya T, et al. Plasma adenosine levels and platelet activation in patients with atrial fibrillation. Am J Cardiol. 1999; 83:194–198. PMID: 10073820

45. Minamino T, Kitakaze M, Sato H, Asanuma H, Funaya H, Kozutsuye Y, et al. Plasma levels of nitrate/nitrite and platelet cGMP levels are decreased in patients with atrial fibrillation. Arterioscler Thromb Vasc Biol. 1997; 17:3191–3195. PMID: 9409310

46. Kahn SR, Solyomoss S, Flegel KM. Nonvalvular atrial fibrillation: evidence for a prothrombotic state. CMAJ. 1997; 157:673–681. PMID: 9307553

47. Sohara H, Amatini S, Kurose M, Miyahara K. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol. 1997; 29:106–112. PMID: 8996302

48. Nagao T, Hamamoto M, Kanda A, Tsuganesawa T, Ueda M, Kobayashi K, et al. Plasma soluble P-selectin and beta-thromboglobulin levels in atrial fibrillation. Stroke. 2002; 33:1237–1242. PMID: 11988597

49. Yamauchi K, Furui H, Taniguchi N, Sotobata I. Plasma beta-thromboglobulin and platelet factor 4 concentrations in patients with atrial fibrillation. Jpn Heart J. 1986; 27:481. PMID: 3195. PMID:9409310

50. Gustafsson C, Blomback M, Britton M, Hamsten A, Svensson J. Coagulation factors and the increased prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol. 2004; 43:1368–1373, A1366. PMID: 20959196

51. Conway DS, Buggins P, Hughes E, Lip GY. Relation of interleukin-6, C-reactive protein, and the prothrombotic state to transeosophageal echocardiographic findings in atrial fibrillation. Am J Cardiol. 2004; 93:1368–1373, A1366. PMID: 15165916

52. Heeringa J, Conway DS, van der Kuip DA, Hofman A, Breteler MM, Lip GY, et al. A longitudinal population-based study of prothrombotic factors in elderly subjects with atrial fibrillation: the Rotterdam Study 1990–1999. J Thromb Haemost. 2006; 4:1944–1949. PMID: 16824187

53. Gartner W, Zierhut B, Mineva I, Sodeck G, Leuntmezer F, Domanovits H, et al. Brain natriuretic peptide correlates with the extent of atrial fibrillation-associated silent brain lesions. Clin Biochem. 2008; 41:1434–1439. doi: 10.1016/j.clinbiochem.2008.09.096 PMID: 18823968
54. Targonski R, Salczynska D, Sadowski J, Cichowski L. Relationship between inflammatory markers and clinical patterns of atrial fibrillation in patients with congestive heart failure. Kardiol Pol. 2008; 66:729–736; discussion 737–729. PMID: 18690564

55. Marcus GM, Whooley MA, Gliddden DV, Pawlikowska L, Zaroff JG, Olgin JE. Interleukin-6 and atrial fibrillation in patients with coronary artery disease: data from the Heart and Soul Study. Am Heart J. 2008; 155:303–309. doi: 10.1016/j.ahj.2007.09.006 PMID: 18215601

56. Roldan V, Marin F, Martinez JG, Garcia-Herola A, Sogorb F, Lip GY. Relation of interleukin-6 levels and prothrombin fragment 1+2 to a point-based score for stroke risk in atrial fibrillation. Am J Cardiol. 2005; 95:881–882. PMID: 15781023

57. Hatzinikolaou-Kotsakou E, Kartasis Z, Tziakas D, Hotidis A, Stakos D, Tsatalas K, et al. Atrial fibrillation and hypercoagulability: dependent on clinical factors or/and on genetic alterations? J Thromb Thrombolysis. 2003; 16:155–161. PMID: 15087601

58. Marin F, Roldan V, Climent V, Garcia A, Marco P, Lip GY. Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1? Stroke. 2003; 34:1181–1186. PMID: 12663879

59. Feng D, D’Agostino RB, Silbershatz H, Lipinska I, Massaro J, Levy D, et al. Hemostatic state and atrial fibrillation (the Framingham Offspring Study). Am J Cardiol. 2001; 87:168–171. PMID: 11152833

60. Giannante C, Fiotti N, Miccio M, Altamura N, Salvi R, Guarnieri G. Coagulation indicators in patients with paroxysmal atrial fibrillation: effects of electric and pharmacologic cardioversion. Am Heart J. 2000; 140:423–429. PMID: 10966540

61. Marin F, Roldan V, Monmeneu JV, Bodi V, Fernandez C, de Burgos FG, et al. Prothrombotic state and elevated levels of plasminogen activator inhibitor-1 in mitral stenosis with and without atrial fibrillation. Am J Cardiol. 1999; 84:862–864, A869. PMID: 10513790

62. Lip GY, Lowe GD, Rumley A, Dunn FG. Fibrinogen and fibrin D-dimer levels in paroxysmal atrial fibrillation: evidence for intermediate elevated levels of intravascular thrombosis. Am J Hematol. 1996; 51:724–730. PMID: 8721646

63. Mitusch R, Siemens HJ, Garbe M, Sheikhzadeh A, Diederich KW. Detection of a hypercoagulable state in nonvalvular atrial fibrillation and the effect of anticoagulant therapy. Thromb Haemost. 1996; 75:219–223. PMID: 8815563

64. Lip GY, Lowe GD, Rumley A, Dunn FG. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br Heart J. 1995; 73:527–533. PMID: 7626351

65. Kumagai K, Fukunami M, Ohmori M, Kitabatake A, Hoki N. Increased intravascular clotting in patients with chronic atrial fibrillation. J Am Coll Cardiol. 1990; 16:377–380. PMID: 2373815

66. Cocco E, Marucci R, Poli D, Antonucci E, Abbate R, Gensini GF, et al. Hyperviscosity as a possible risk factor for cerebral ischemic complications in atrial fibrillation patients. Am J Cardiol. 2006; 97:1745–1748. PMID: 16765126

67. Topcuoglu MA, Haydari D, Ozturk S, Ozcebe OI, Saribas O. Plasma levels of coagulation and fibrinolytic markers in acute ischemic stroke patients with lone atrial fibrillation. Neuronal Sci. 2000; 21:235–240. PMID: 11214663

68. Tsai LM, Chen JH, Tsao CJ. Relation of left atrial spontaneous echo contrast with prothrombotic state in atrial fibrillation associated with systemic hypertension, idiopathic dilated cardiomyopathy, or no identifiable cause (lone). Am J Cardiol. 1998; 81:1249–1252. PMID: 9604963

69. Zorlu A, Akkaya E, Altay H, Bektasoglu G, Turkdogan KA, Sincer I, et al. The relationship between D-dimer level and the development of atrial fibrillation in patients with systolic heart failure. J Thromb Thrombolysis. 2012; 33:343–348. doi: 10.1007/s11239-011-0656-8 PMID: 22139027

70. Adamsson Eryd S, Smith JG, Melander O, Hedblad B, Engstrom G. Inflammation-sensitive proteins and risk of atrial fibrillation: a population-based cohort study. Eur J Epidemiol. 2011; 26:449–455. doi: 10.1007/s10654-011-9565-6 PMID: 21424216

71. Alonso A, Tang W, Agarwal SK, Soliman EZ, Chamberlain AM, Folsom AR. Hemostatic markers are associated with the risk and prognosis of atrial fibrillation: the ARIC study. Int J Cardiol. 2012; 155:217–222. doi: 10.1016/j.ijcard.2010.09.051 PMID: 20965585

72. Schnabel RB, Larson MG, Yamamoto JF, Sullivan LM, Pencina MJ, Meigs JB, et al. Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. Circulation. 2010; 121:200–207. doi: 10.1161/CIRCULATIONAHA.109.882241 PMID: 20048208

73. Colman RW CA, George JN, Goldhaber SZ, Marder VJ. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th edn. JB Lippincott Co; 2006.

74. Lip GY. Does atrial fibrillation confer a hypercoagulable state? Lancet. 1995; 346:1313–1314. PMID: 7475767
75. Akar JG, Jeske W, Wilber DJ. Acute onset human atrial fibrillation is associated with local cardiac platelet activation and endothelial dysfunction. J Am Coll Cardiol. 2008; 51:1790–1793. doi: 10.1016/j.jacc.2007.11.083 PMID: 18452786

76. Shiroshita-Takeshita A, Brundel BJ, Nattel S. Atrial fibrillation: basic mechanisms, remodeling and triggers. J Interv Card Electrophysiol. 2005; 13:181–193. PMID: 16177845

77. Wu N, Xu B, Xiang Y, Wu L, Zhang Y, Ma X, et al. Association of inflammatory factors with occurrence and recurrence of atrial fibrillation: A meta-analysis. Int J Cardiol. Int J Cardiol. 2013; 169:62–72. doi: 10.1016/j.ijcard.2013.08.078 PMID: 24095158

78. Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol. 2012; 60:2263–2270. doi: 10.1016/j.jacc.2012.04.063 PMID: 23194937

79. Chung NA, Belgore F, Li-Saw-Hee FL, Conway DS, Blann AD, Lip GY. Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor? Stroke. 2002; 33:2187–2191. PMID: 12215585

80. Das UN. Is angiotensin-II an endogenous pro-inflammatory molecule? Med Sci Monit. 2005; 11: RA155–162. PMID: 15874906

81. Vene N, Mavri A, Kosmelj K, Stegnar M. High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy. Thromb Haemost. 2003; 90:1163–1172. PMID: 14652652

82. Ha SI, Choi DH, Ki YJ, Yang JS, Park G, Chung JW, et al. Stroke prediction using mean platelet volume in patients with atrial fibrillation. Platelets. 2011; 22:408–414. doi: 10.3109/09537104.2011.560306 PMID: 21599611

83. Roldan V, Marin F, Muina B, Torregrosa JM, Hernandez-Romero D, Valdes M, et al. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol. 2011; 57:2496–2504. doi: 10.1016/j.jacc.2010.12.033 PMID: 21497043